eligibility_summary
Eligible: Adults with confirmed relapsed/refractory multiple myeloma, for whom the physician plans equecabtagene autoleucel, and who provide informed consent. Exclude: Allergic to the product or excipients (DMSO, compound electrolyte injection, human albumin), unable to attend follow-ups/complete the study, or life expectancy under 3 months.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: Equecabtagene autoleucel (CT103A) — an autologous, fully human, anti-BCMA chimeric antigen receptor T‑cell (CAR‑T) therapy (cellular gene therapy/adoptive cell therapy) for relapsed/refractory multiple myeloma. Mechanism of action: Patient T cells are genetically engineered to express a CAR that binds B‑cell maturation antigen (BCMA) on myeloma cells. Antigen engagement triggers CAR intracellular activation domains, driving T‑cell expansion, cytokine release, and cytotoxic killing via perforin/granzymes, leading to elimination of BCMA+ plasma cells. Targets/pathways: BCMA (TNFRSF17) on malignant plasma cells, impacting the BAFF/APRIL–BCMA survival axis, activation of T‑cell effector pathways.